These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis. Callhoff J; Weiß A; Zink A; Listing J Rheumatology (Oxford); 2013 Dec; 52(12):2127-35. PubMed ID: 23946435 [TBL] [Abstract][Full Text] [Related]
5. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208 [TBL] [Abstract][Full Text] [Related]
6. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Mandema JW; Salinger DH; Baumgartner SW; Gibbs MA Clin Pharmacol Ther; 2011 Dec; 90(6):828-35. PubMed ID: 22048227 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Symmons DP; Watson KD; Silman AJ; Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520 [TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA; Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444 [TBL] [Abstract][Full Text] [Related]
9. Are All Biologics the Same? Optimal Treatment Strategies for Patients With Early Rheumatoid Arthritis: Systematic Review and Indirect Pairwise Meta-Analysis. Albert DA J Clin Rheumatol; 2015 Dec; 21(8):398-404. PubMed ID: 26226612 [TBL] [Abstract][Full Text] [Related]
10. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P Sao Paulo Med J; 2010; 128(5):309-10. PubMed ID: 21181074 [TBL] [Abstract][Full Text] [Related]
11. Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. Tvete IF; Natvig B; Gåsemyr J; Meland N; Røine M; Klemp M PLoS One; 2015; 10(9):e0137258. PubMed ID: 26356639 [TBL] [Abstract][Full Text] [Related]
12. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443 [TBL] [Abstract][Full Text] [Related]
13. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data? Levesque MC BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403 [TBL] [Abstract][Full Text] [Related]
14. Remission in rheumatoid arthritis: wishful thinking or clinical reality? Sesin CA; Bingham CO Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons. Barra L; Ha A; Sun L; Fonseca C; Pope J Clin Exp Rheumatol; 2014; 32(3):333-41. PubMed ID: 24480452 [TBL] [Abstract][Full Text] [Related]
16. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132 [TBL] [Abstract][Full Text] [Related]
17. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. Farahani P; Levine M; Gaebel K; Thabane L Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497 [TBL] [Abstract][Full Text] [Related]
18. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Grijalva CG; Chung CP; Arbogast PG; Stein CM; Mitchel EF; Griffin MR Med Care; 2007 Oct; 45(10 Supl 2):S66-76. PubMed ID: 17909386 [TBL] [Abstract][Full Text] [Related]
19. Examining the efficacy of biologic therapy: are there real differences? Fleischmann RM J Rheumatol Suppl; 2002 Sep; 65():27-32. PubMed ID: 12236619 [TBL] [Abstract][Full Text] [Related]